The Risks, Benefits, and Uncertainties of Stepping Down Asthma Medications

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 5, 2014, Pages 503-509

  Rank, Matthew A ^a   Peters, Stephen P ^b  

^a MAYO CLINIC   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Anti asthmatic agents; Asthma; Cessation; Decrease; Discontinue; Step down; Wean; Withdraw

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; EOTAXIN; LEUKOTRIENE RECEPTOR STIMULATING AGENT; LONG ACTING BETA AGONIST; NITRIC OXIDE; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT;

AGE; ARTICLE; ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; BRONCHUS DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE DURATION; DISEASE EXACERBATION; DRUG COST; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; MEDICATION COMPLIANCE; PATIENT DECISION MAKING; PATIENT PREFERENCE; PHARMACOGENETICS; POINT OF CARE TESTING; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT FAILURE; RISK ASSESSMENT; UNCERTAINTY;

ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; PATIENT PREFERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; UNCERTAINTY;

EID: 84918832074     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.03.004     Document Type: Article

References (54)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2011 update. Available from: . Accessed December 29, 2013. http://www.ginasthma.org/uploads/users/files/GINA_Report_2011.pdf.
2. National Heart Lung and Blood Institute. National Asthma Education and Prevention Program. Available from: . Accessed December 29, 2013. http://www.nhlbi.nih.gov/about/naepp/.
3. Kelly H.W., Sternberg A.L., Lescher R., Fuhlbrigge A.L., Williams P., Zeiger R.S., et al. Effect of inhaled glucocorticoids in childhood on adult height. NEngl J Med 2012, 367:904-912.
4. McKeever T., Harrison T.W., Hubbard R., Shaw D. Inhaled corticosteroids and the risk of pneumonia in people with asthma: a case-control study. Chest 2013, 144:1788-1794.
5. Chowdhury B.A., Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. NEngl J Med 2010, 362:1169-1171.
6. Fanta C.H. Asthma. NEngl J Med 2009, 360:1002-1014.
7. Montori V.M., Brito J.P., Murad M.H. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA 2013, 310:2503-2504.
8. Clearie K.L., Jackson C.M., Fardon T.C., Williamson P.A., Vaidyanathan S., Burns P., et al. Supervised step-down of inhaled corticosteroids in the community: an observational study. Respir Med 2011, 105:558-565.
9. Ubel P.A., Abernethy A.P., Zafar S.Y. Full disclosure: out-of-pocket costs as side effects. NEngl J Med 2013, 369:1484-1486.
10. Rank M.A., Liesinger J.T., Ziegenfuss J.Y., Branda M.E., Lim K.G., Yawn B.P., et al. Asthma expenditures in the United States comparing 2004 to 2006 and 1996 to 1998. Am J Manag Care 2012, 18:499-504.
11. Guest J.F., Davie A.M., Ruiz F.J., Greener M.J. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J 2005, 14:88-98.
12. Godard P., Greillier P., Pigearias B., Nachbaur G., Desfougeres J.L., Attali V. Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomized study. Respir Med 2008, 102:1124-1131.
13. Koenig S.M., Ostrom N., Pearlman D., Waitkus-Edwards K., Yancey S., Prilaman B.A., et al. Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down.". JAsthma 2008, 45:681-687.
14. Berger W.E., Bleeker E.R., O'Dowd L., Miller C.J., Mezzanotte W. Efficacy and safety of budesonide/formoterol pressured metered-dose inhaler: randomized controlled trial comparing once-and twice-daily dosing in patients with asthma. Allergy Asthma Proc 2010, 31:49-59.
15. Reddel H.K., Gibson P.G., Peters M.J., Wark P.A., Sand I.B., Hoyos C.M., et al. Down-titration from high-dose combination therapy in asthma: removal of long-acting beta(2)-agonist. Respir Med 2010, 104:1110-1120.
16. Brozek J.L., Kraft M., Krishnan J.A., Cloutier M.M., Lazarus S.C., Li J.T., et al. Long-acting β2-agonist step-off in patients with controlled asthma. Arch Intern Med 2012, 172:1365-1375.
17. Juniper E.F., Kline P.A., Vanzieleghem M.A., Hargreave F.E. Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. JAllergy Clin Immunol 1991, 87:483-489.
18. ZuWallack R.L., Rosen J.P., Cohen L., Rachelefsky G.S., Gong H., Goldsobel A.B., et al. The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control. JAllergy Clin Immunol 1997, 99:278-285.
19. Visser M.L., Postma D.S., Arends L.R., de Vries T.W., Duiverman E.J., Brand P.L. One-year treatment with different dosing schedules of fluticasone propionate in childhood asthma. Am J Respir Crit Care Med 2001, 164:2073-2077.
20. Hawkins G., McMahon A.D., Twaddle S., Wood S.F., Ford I., Thomson N.C. Stepping down inhaled corticosteroids in asthma: a randomized controlled trial. BMJ 2003, 326:1115.
21. Martinez F.D., Chinchilli V.M., Morgan W.J., Boehmer S.J., Lemanske R.F., Mauger D.T., et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomized, double-blind, placebo-controlled trial. Lancet 2011, 377:650-657.
22. Papi A., Canonica G.W., Maestrelli P., Paggiaro P., Olivieri D., Pozzi E., et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. NEngl J Med 2007, 356:2040-2052.
23. Hagan J.B., Samant S.A., Volcheck G.V., Li J.T., Hagan C.R., Erwin P.J., et al. The risk of asthma exacerbation after reducing inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. Allergy 2014, 69:510-516.
24. Price D., Chisholm A., Hillyer E.V., Burden A., von Ziegenweidt J., Svedsater H., et al. Effect of inhaled corticosteroid therapy step-down and dosing regimen on measures of asthma control. JAllergy Ther 2013, 4:1-8.
25. Randomized comparison of strategies for reducing treatment in mild persistent asthma. NEngl J Med 2007, 356:2027-2039. American Lung Association Asthma Clinical Research Network.
26. Kelloway J.S., Wyatt R.A., Adlis S.A. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994, 154:1349-1352.
27. Sherman J., Patel P., Hutson A., Chesrown S., Hendeles L. Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma. Pharmacotherapy 2001, 21:1464-1467.
28. Tan H., Sarawate C., Singer J., Elward K., Cohen R.I., Smart B.A., et al. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes. Mayo Clin Proc 2009, 84:675-684.
29. Rank M.A., Hagan J.B., Park M.A., Podjasek J.C., Samant S.A., Volcheck G.W., et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systemic review and meta-analysis of randomized controlled trials. JAllergy Clin Immunol 2013, 131:724-729.
30. Waalkens H.J., Van Essen-Zandvliet E.E., Hughes M.D., Gerritsen J., Duiverman E.F., Knol K., et al. Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993, 148:1252-1257.
31. Haahtela T., Jarvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. NEngl J Med 1994, 331:700-705.
32. Condemi J.J., Chervinsky P., Goldstein M.F., Ford L.B., Berger W.E., Ayars G.H., et al. Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients with persistent asthma. JAllergy Clin Immunol 1997, 100:467-474.
33. 2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001, 285:2583-2593.
34. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from: . Accessed December 18, 2013. http://www.cochrane-handbook.org.
35. Tsurikisawa N., Oshikata C., Tsuburai T., Mitsui C., Tanimoto H., Takahashi K., et al. Markers for step-down of inhaled corticosteroid therapy in adult asthmatics. Allergol Int 2012, 61:419-429.
36. Tonelli M., Bacci E., Dente F.L., Bartoli M.L., Cianchetti S., Di Franco A., et al. Predictors of symptom recurrence after low-dose inhaled corticosteroid cessation in mild persistent asthma. Respir Med 2006, 100:622-629.
37. Leuppi J.D., Salome C.M., Jenkins C.R., Anderson S.D., Xuan W., Marks G.B., et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001, 163:406-412.
38. Belda J., Parameswaran K., Lemiere C., Kamada D., O'Byrne P.M., Hargreave F.E. Predictors of loss of asthma control induced by corticosteroid withdrawal. Can Resp J 2006, 13:129-133.
39. Baba K., Sakakibara A., Yagi T., Niwa S., Wakayama H., Takagi K. Long-term observations of the clinical course after step down of corticosteroid inhalation therapy in adult chronic asthmatics: correlation with serum levels of eosinophil cationic protein. Respirology 2002, 7:255-266.
40. Zacharasiewicz A., Wilson N., Lex C., Erin E.M., Li A.M., Hansei T., et al. Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children. Am J Respir Crit Care Med 2005, 171:1077-1082.
41. Kwong K.Y.C., Morphew T., Huynh P., Scott L., Radjal N., Dale G. Loss of asthma control in inner city children with asthma after withdraw of asthma controller medication. JAsthma 2009, 46:1001-1005.
42. Obase Y., Ikeda M., Kurose K., Abe M., Shimizu H., Ohue Y., et al. Step-down of budesonide/formoterol in early stages of asthma treatment leads to insufficient anti-inflammatory effect. JAsthma 2013, 50:718-721.
43. Ciolkowski J., Mazurek H., Stasiowska B. Evaluation of step-down therapy from an inhaled steroid to montelukast in childhood asthma. Allergol Immunopathol (Madr) 2013, May 16, [Epub ahead of print].
44. Rank M.A., Branda M.E., McWilliams D.B., Johnson S.K., Samant S.A., Podjasek J.C., et al. Outcomes of stepping down asthma medications in a guideline-based pediatric asthma management program. Ann Allergy Asthma Immunol 2013, 110:354-358.
45. Rank M.A., Ziegenfuss J.Y., Shah K.M., Jenkins S.M., Lackore K.A., Eton D.T., et al. Factors associated with decisions to step down asthma medications. JAllergy Clin Immunol Pract 2013, 1:312-314.
46. Yawn B.P., Wollan P.C., Bertram S.L., Lowe D., Butterfield J.H., Bonde D., et al. Asthma treatment in a population-based cohort: putting step-up and step-down treatment changes in context. Mayo Clin Proc 2007, 82:414-421.
47. Hoffmann H.J., Nielsen L.P., Harving H., Heinig J.H., Dahl R. Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11. Clin Respir J 2008, 2:149-157.
48. Mougey E.B., Chen C., Tantisira K.G., Blake K.V., Peters S.P., Wise R.A., et al. Pharmacogenetics of asthma controller treatment. Pharmacogenomics J 2013, 13:242-250.
49. Drummond M.B., Peters S.P., Castro M., Holbrook J.T., Irvin C.G., Smith L.J., et al. Risk factors for montelukast treatment failure in step-down therapy for controlled asthma. JAsthma 2011, 48:1051-1057.
50. Calhoun W.J., Ameredes B.T., King T.S., Icitovic N., Bleecker E.R., Castro M., et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA 2012, 308:987-997.
51. Boushey H.A., Sorkness C.A., King T.S., Sullivan S.D., Fahy J.V., Lazarus D.C., et al. Daily versus as-needed corticosteroids for mild persistent asthma. NEngl J Med 2005, 352:1519-1528.
52. Hashimoto S., Ten Brinke A., Roldaan A.C., van Zeen I.H., Moller G.M., Sont J.K., et al. Internet-based tapering of oral corticosteroids in severe asthma: a pragmatic randomised controlled trial. Thorax 2011, 66:514-520.
53. Powell H., Gibson P.G. High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Cochrane Database Syst Rev 2009, 4.
54. Wilson S.R., Strub P., Buist A.S., Knowles S.B., Lavori P.W., Lapidus J., et al. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am J Resp Crit Care Med 2010, 181:566-577.